Results 71 to 80 of about 86,262 (260)

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement–interleukin-1β loop

Haematologica, 2019
Enhanced peripheral complement activation has long been considered as one of the major pathogenic elements of immune thrombocytopenia. A dysfunctional bone marrow microenvironment, especially with regards to mesenchymal stem cells, has been observed in ...
Xiaolu Zhu, Yanan Wang, Qian Jiang, Hao Jiang, Jin Lu, Yazhe Wang, Yuan Kong, Yingjun Chang, Lanping Xu, Jun Peng, Ming Hou, Xiaojun Huang, Xiaohui Zhang   +12 more
doaj   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source

Experimental Models of Thrombocytopenia in Laboratory Animals and their Application in Identifying the Complications of Chemotherapy Drugs

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2018
BACKGROUND AND OBJECTIVE: Thrombocytopenia is one of the complications of chemotherapy drugs that may cause death. Different animal models of thrombocytopenia are used for clinical research and identification of its causes, each with advantages and ...
H Kamali, MR Khazaei, E Shobeiri, M Khazaei   +3 more
doaj  

Metronidazole caused profound drug‐induced immune thrombocytopenia

Clinical Case Reports, 2018
Key Clinical Message Metronidazole is commonly prescribed and has not been known to cause drug‐induced immune thrombocytopenia. We have provided clinical and laboratory evidence with DDabs that metronidazole can cause drug‐induced immune thrombocytopenia
Jeffrey Lew, Jeffrey Berenberg
doaj   +1 more source

Immune Thrombocytopenia as a Consequence of Rocky Mountain Spotted Fever

Case Reports in Oncology, 2017
Primary immune thrombocytopenia (ITP) – also called idiopathic thrombocytopenic purpura or immune thrombocytopenic purpura – is an acquired thrombocytopenia caused by autoantibodies against platelet antigens.
Cherisse Baldeo, Karan Seegobin, Lara Zuberi   +2 more
doaj   +1 more source

Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics

Clinical Pharmacology &Therapeutics, EarlyView.
Postmarketing safety surveillance data identify safety issues not identified in preapproval clinical trials. We describe the frequency of new safety issues overall and by labeling section and the relationship of the most commonly added safety issues with the cumulative number of prescriptions dispensed via retail pharmacies.
Ellen Pinnow, Brendan Day, Esther H. Zhou, Corinne Woods, Nana Dwumfour, Jenni Y. Lee, Ilynn Bulatao, Sanae Cherkaoui, Manish Kalaria, Sonja Brajovic, Nabila Sadiq, Farideh Sistani, Maggie Lee, Grace Chai, Gerald Dal Pan   +14 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Immune thrombocytopenia.

South Dakota medicine : the journal of the South Dakota State Medical Association, 2014
Immune thrombocytopenia (ITP) in children is a relatively uncommon and generally benign condition presenting as abrupt onset of bruising, petechiae and thrombocytopenia in an otherwise healthy child due to production of anti-platelet autoantibodies. Diagnosis is largely clinical and laboratory investigation should be kept to a minimum.
Yoji Ishida, Akiyoshi Takami, Akira Hangaishi, Tomoaki Shishido, Kanae Akita   +4 more
openaire   +4 more sources

Immune-Mediated Thrombocytopenia

Veterinary Quarterly, 1998
• Immune-mediated thrombocytopenia (IMTP) is rare and poorly documented in the cat (in contrast to the dog). • Cause: most cases are likely to be secondary (particularly to FeLV infection and associated neoplasia) rather than primary autoimmune thrombocytopenia (AITP). • Signs: vague eg anorexia, lethargy.
openaire   +2 more sources